Physician profile
Richard E Ramsay
NPI 1790740694
$252,658.48
in general payments reported to CMS, 2019-2025
51 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $38K · 2021: $26K · 2022: $66K · 2023: $32K · 2024: $23K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $41K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $6,190 · Travel and Lodging: $4,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $40,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,631.00 |
| Food and Beverage | $6,189.57 |
| Travel and Lodging | $4,039.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $133,100.05 | 2020-2025 | Xcopri |
| Neurelis, INC. | $44,622.42 | 2020-2025 | Valtoco |
| Ucb, INC. | $38,165.50 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Eisai INC. | $29,497.27 | 2019-2021 | |
| West Therapeutics Development, LLC | $1,750.00 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $1,160.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $652.97 | 2022-2025 | Epidiolex |
| Sunovion Pharmaceuticals INC. | $450.08 | 2019-2020 | |
| Amgen INC. | $415.39 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $305.78 | 2024-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $227.55 | 2019-2025 | Ingrezza |
| Argenx US, INC. | $174.07 | 2024-2025 | Vyvgart Hytrulo |
| Abbvie INC. | $169.09 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $167.21 | 2024-2025 | Ultomiris |
| Greenwich Biosciences, INC. | $142.58 | 2019 |
Show all 49 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ramsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.